Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
Analyst Daniel Brennan of TD Cowen maintained a Hold rating on 10x Genomics (TXG – Research Report), retaining the price target of $18.00. Daniel Brennan has given his Hold rating due to a combination ...
Analyst Michael Ryskin of Bank of America Securities reiterated a Sell rating on 10x Genomics (TXG – Research Report), with a price target of $36.00. Michael Ryskin has given his Sell rating due to a ...
PacBio (PACB), a leading developer of high-quality, highly accurate genomic sequencing solutions, today announced the inclusion of the Onso short-read sequencing platform in the 10x Genomics ...
PLEASANTON, Calif., Feb. 23, 2025 /PRNewswire/ — At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, ...
PLEASANTON — 10x Genomics has marked a new phase in its remarkable expansion by opening a modern office building that has just sprouted in Pleasanton, coupled with plans for even more growth at its ...
Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, and 10x Genomics, Inc., a leader in single cell and spatial biology, today announced a new partnership to expand ...
PLEASANTON, Calif., March 3, 2025 /PRNewswire/ — 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.
10x Genomics will host a workshop at AGBT today, Sunday, February 23, at 1 p.m. ET to share the latest data and development directions across its three platforms. This workshop will be live-streamed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results